Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb to buy Cardioxyl Pharmaceuticals
Cardioxyl is focused on the discovery and development of novel therapeutic agents to treat cardiovascular disease. The transaction, which is expected to close in the fourth quarter, gives
Cardioxyl is focused on the discovery and development of novel therapeutic agents to treat cardiovascular disease. The transaction, which is expected to close in the fourth quarter, gives
The other investors in PrEP Biopharm include Johnson & Johnson Innovation – JJDC and US-based angel investors. hVIVO will acquire a significant interest in PrEP Biopharm for £14m,
The three-year collaboration builds on the framework the companies have developed under a cancer metabolism partnership, which started in 2013. Merck and Selvita will contribute funding and resources
Earlier this year, Isis signed a license agreement with Bayer HealthCare for the development and commercialization of ISIS-FXIRx to prevent clotting disorders. Upon completion of ongoing activities at
Pexidartinib is an investigational novel, oral small molecule that selectively inhibits a primary growth driver of abnormal cells in the synovium that causes TGCT called colony stimulating factor-1
It is the fifth indication for Eylea, which is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. Bayer is co-developing Eylea with
Vidaza is indicated to treat adult patients aged 65 years or older with AML who are not eligible for haematopoietic stem cell transplantation (HSCT). The commission updated Vidaza
The companies have signed collaboration and licensing agreement, which is expected to generate $1.56bn for Arcturus. In the first phase of the collaboration, Arcturus will design and optimize
The 150-subject, randomized, open-label, multi-center clinical trial will compare the combination regimen to RICE alone. The primary endpoint is the comparison of complete remission rates between the two
Allergan said it had been approached by Pfizer and is in preliminary friendly negotiations with respect to a potential business combination. The company said no agreement has been